Quantcast

Latest endocrine therapy Stories

2012-07-02 23:11:52

Preclinical imaging of progesterone receptor signals usefulness of biomarker in determining effectiveness of therapy Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage. Estrogen receptor-α(ERα) status is an important factor in determining the most appropriate treatment for breast cancer patients,...

2012-05-18 11:39:57

Researchers from Baylor College of Medicine have been awarded more than $5 million from Susan G. Komen for the Cure for three new breast cancer research grants, including a prestigious Komen Promise Grant. Komen Promise Grant The Komen Promise Grant is a three-year award for a total of $4,066, 940 to study restoration of endocrine therapy sensitivity in recurrent breast cancers. The grant was awarded to principal investigator Dr. Bert O'Malley, chair of molecular and cellular biology at...

2011-12-10 06:49:25

(Ivanhoe Newswire) -- Aside from all the other health issues obesity can cause, here is another one to add to the list. According to a recent study, obesity is associated with worse outcomes overall in early-stage breast cancer. Obesity was linked to shorter time to recurrence, disease-free survival and overall survival. The exception was treatment with endocrine therapy, in which obesity was associated with a protective effect. "The findings add to the body of evidence indicating that...

2011-12-08 12:57:18

Obesity is associated with worse outcomes overall in early-stage breast cancer, researchers reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011. Obesity was linked to shorter time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS). The exception was treatment with endocrine therapy (mainly tamoxifen), in which obesity was associated with a protective effect. "The findings add to the body of evidence indicating that obesity, in...

2011-12-07 11:25:09

Knowing biology of early or late recurring tumors could help extend survival by identifying interventions to delay or prevent recurrences after tamoxifen An international research team led by Georgetown Lombardi Comprehensive Cancer Center has found biological differences in hormone-receptor positive breast cancer that are linked to the timing of recurrence despite endocrine therapy. They say their findings, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, may help...

2011-06-16 13:08:18

The first roadmap to mathematical modeling of a powerful basic "decision circuit" in breast cancer has been developed and published in Nature Reviews Cancer. The preliminary mathematical model is the first result of a $7.5 million federal grant, awarded to scientists at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) and collaborators at Virginia Tech and Fox Chase Cancer Center, to develop a systems approach to understanding and treating one of the...

2011-05-11 01:00:54

Tool may one day be used to guide patients' treatment with standard therapy alone, or personalized clinical trial upfront A new genomic test combining multiple signatures "“ a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity "“ shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center. The...

2011-05-11 00:56:43

Development of a predictive test that included genomic signatures that indicated chemoresistance, chemosensitivity and endocrine sensitivity for women with newly diagnosed breast cancer identified patients with a high probability of survival following chemotherapy, according to a study in the May 11 issue of JAMA. Identification of patients with high likelihood of survival following a standard chemotherapy regimen (and then endocrine therapy, if estrogen receptor [ER]-positive) would reaffirm...

2010-08-05 06:30:00

Grant awarded to Dr. Jacek Pinski to conduct the study at the Norris Comprehensive Cancer Center of the University of Southern California QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer...

2010-07-14 10:15:00

QUEBEC CITY, July 14 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc. ("Keryx") (Nasdaq: KERX), has been granted orphan-drug designation by the U.S. Food and Drug Administration ("FDA") for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related